Login / Signup

Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours.

Aditya BagrodiaAnna SavelyevaJohn T LafinRyan W SpeirGregory T ChesnutAnne Lindsay FrazierSolomon L WolduVitaly MargulisMatthew Jonathan MurrayJames F AmatrudaYair Lotan
Published in: BJU international (2020)
A miRNA-based approach may potentially select patients with Stage I NSGCT for correct treatment in a cost-effective manner. Identification of residual teratoma-only remains an issue. Prospective studies are necessary to validate these findings.
Keyphrases
  • germ cell
  • type diabetes
  • metabolic syndrome
  • adipose tissue
  • replacement therapy
  • bioinformatics analysis